Lisa DeFrancesco

CIK: 0001846325

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)3 (33.3%)

Derivative conversions

Awards (A)4 (44.4%)

Compensation grants

Other (G, F, J, C, D, …)2 (22.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LXRX

LEXICON PHARMACEUTICALS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 28, 2026
Tax Payment(F)
Direct
74.6K shares at avg. $1.47$110K
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 28, 2026
Exercise(M)
Direct
128.2K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 28, 2026
Exercise(M)
Direct
24.7K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 12, 2026
Award(A)
Restricted Stock Units
Direct
257.5K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
386.3K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 28, 2025
Tax Payment(F)
Direct
9.1K shares at avg. $0.67$6K
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 28, 2025
Exercise(M)
Direct
24.7K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
576.9K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 13, 2025
Award(A)
Restricted Stock Units
Direct
384.6K shares-

		Type	Shares	Price		Ownership
Feb 28, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Tax Payment(F)	74,572	$1.47	$109,621	Direct
Feb 28, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Exercise(M)	128,190	-	$0	Direct
Feb 28, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Exercise(M)	24,674	-	$0	Direct
Feb 12, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Award(A) Restricted Stock Units	257,530	-	-	Direct
Feb 12, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Award(A) Stock Option (Right to Buy)	386,300	-	-	Direct
Feb 28, 2025	LXRX LEXICON PHARMACEUTICALS, INC.	Tax Payment(F)	9,096	$0.67	$6,094	Direct
Feb 28, 2025	LXRX LEXICON PHARMACEUTICALS, INC.	Exercise(M)	24,673	-	-	Direct
Feb 13, 2025	LXRX LEXICON PHARMACEUTICALS, INC.	Award(A) Stock Option (Right to Buy)	576,850	-	-	Direct
Feb 13, 2025	LXRX LEXICON PHARMACEUTICALS, INC.	Award(A) Restricted Stock Units	384,570	-	-	Direct

1-9 of 9 transactions

About DeFrancesco Lisa

DeFrancesco Lisa (SEC CIK 0001846325) files insider reports with the SEC as SVP, IR and Corp Comm of LEXICON PHARMACEUTICALS, INC. (LXRX).

Signal8 holds 5 ownership filings by DeFrancesco Lisa (1 Form 3, 4 Form 4), filed between Oct 7, 2024 and Mar 3, 2026. Those filings report 9 transactions, from Feb 13, 2025 to Feb 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DeFrancesco Lisa's filings is in SPRING, TX.

Recent filings by DeFrancesco Lisa

Feb 28, 2026: Tax withholding of LXRX shares (Form 4, code F).
Feb 28, 2026: Option exercises of LXRX shares (2 lines, Form 4, code M).
Feb 12, 2026: Grants or awards of LXRX derivative securities (2 lines, Form 4, code A).
Feb 28, 2025: Tax withholding of LXRX shares (Form 4, code F).
Feb 28, 2025: Option exercise of LXRX shares (Form 4, code M).

Other insiders filing for LEXICON PHARMACEUTICALS, INC. (LXRX)

Swain Judith L, Director
Sullivan Diane E., Director
SOBECKI CHRISTOPHER J, Director
Cheung Ivan, Director
BARKER SAM L, Director
Amouyal Philippe, Director

How to read Form 4 transaction codes